The Evolving Treatment Landscape of Small Cell Lung Cancer : Episode 8

Video

July 18, 2022

Ongoing Trials and Real-World Studies in Frontline SCLC

Author(s):

Charu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD

Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.

EP: 1.Overview of SCLC and Importance of Early Diagnosis

EP: 2.Use of the TNM Staging System in SCLC

EP: 3.Progress in the Treatment and Management of SCLC

EP: 4.Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

EP: 5.Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

EP: 6.Management of Adverse Events Associated with Durvalumab + Chemotherapy

EP: 7.IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

Now Viewing

EP: 8.Ongoing Trials and Real-World Studies in Frontline SCLC

EP: 9.Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

EP: 10.Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

EP: 11.Lurbinectedin for SCLC Treatment in the Second-Line Setting

EP: 12.Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

EP: 13.Choosing the Appropriate Treatment in the Second Line Setting in SCLC

EP: 14.Investigational Agents in SCLC in the Second Line Setting and Beyond

EP: 15.Clinical Practice Pearls and the Future of SCLC

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Related Content

March 17th 2025

Durvalumab Secures EU Approval for LS-SCLC After CRT

December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

MT-8421 in Advanced Solid Tumors | Image Credit: © Cornflakesei – stock.adobe.com

March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

NSCLC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com

March 11th 2025

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC

Related Content

March 17th 2025

Durvalumab Secures EU Approval for LS-SCLC After CRT

December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC

Ongoing Trials and Real-World Studies in Frontline SCLC

EP: 1.Overview of SCLC and Importance of Early Diagnosis

EP: 2.Use of the TNM Staging System in SCLC

EP: 3.Progress in the Treatment and Management of SCLC

EP: 4.Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

EP: 5.Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

EP: 6.Management of Adverse Events Associated with Durvalumab + Chemotherapy

EP: 7.IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

EP: 8.Ongoing Trials and Real-World Studies in Frontline SCLC

EP: 9.Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

EP: 10.Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

EP: 11.Lurbinectedin for SCLC Treatment in the Second-Line Setting

EP: 12.Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

EP: 13.Choosing the Appropriate Treatment in the Second Line Setting in SCLC

EP: 14.Investigational Agents in SCLC in the Second Line Setting and Beyond

EP: 15.Clinical Practice Pearls and the Future of SCLC

Newsletter

Latest Conference Coverage